Randomized, Double-Blind Phase 2b Data in 327 Patients, Plus New Mechanistic Research, to Be Presented October 23 in Denver Kibow Therapeutics, a clinical-stage biotechnology company advancing microbiome-based therapies for chronic…
Kibow Therapeutics is a phase 2 clinical-stage company focused on developing novel live biotherapeutic products (LBP) for chronic kidney disease (CKD) patients. Kibow’s first clinical product, KT-301, is in a…
Kibow Biotech, Inc., a clinical-stage biotechnology company pioneering the discovery and development of probiotics and prebiotics (synbiotics) for the treatment of kidney diseases beyond gut health, today announced that the…
The 4th annual Kidney Patient Summit is to be held on March 6th and 7th in Washington DC. At this unique event, nearly 150 advocates from six different kidney disease organizations…